Sunscreen Active Ingredient Stability Testing: What ICH Q1B and FDA's OTC Monograph Actually Require

Avobenzone — the broadest-spectrum UVA filter approved for use in the United States — can degrade by more than 36% in just 60 minutes of direct sunlight when it’s formulated without a photostabilizer. That’s not a fringe finding from an obscure study; it’s been reproduced in peer-reviewed literature for over two decades. Yet walk down any drugstore aisle in 2026 and you’ll find avobenzone-containing SPF products with no photostabilizer listed anywhere on the label, and no publicly available stability data behind the claim.

For any brand formulating a sunscreen product for the US market, this is the core tension you’re managing: UV filters are inherently reactive to the very radiation they’re designed to block. The testing protocols designed to catch this problem — primarily ICH Q1B photostability testing and the FDA’s OTC drug monograph framework — are specific, demanding, and frequently misunderstood. Getting them wrong doesn’t just create a regulatory problem. It means your product may be far less effective than the label claims by the time a consumer actually uses it.

Why Sunscreen Actives Are Treated as Drugs, Not Cosmetics

The first thing any brand needs to internalize is that in the United States, sunscreen products are regulated as over-the-counter (OTC) drugs under FDA authority — not as cosmetics. This distinction has real consequences for testing requirements, and it’s the reason ICH pharmaceutical guidelines apply directly to your SPF moisturizer.

Because sunscreens carry drug status, they fall under a monograph system that specifies which active ingredients are permitted, at what concentrations, and with what labeling. FDA’s 2019 proposed rule updated that monograph significantly. Of the 16 UV filter ingredients evaluated, only two — zinc oxide (up to 25%) and titanium dioxide (up to 25%) — received Category I status, meaning they’re generally recognized as safe and effective (GRASE). Two ingredients — PABA and trolamine salicylate — were placed in Category II (not GRASE). The remaining 12 organic filters, including avobenzone, oxybenzone, and octinoxate, landed in Category III: insufficient data to determine GRASE status.

Those 12 Category III ingredients aren’t prohibited. They’re still being used. But the regulatory picture around them is genuinely unsettled, and FDA has been clear that additional safety and effectiveness data will be required before any of them can move out of Category III. That unsettled status creates both urgency and opportunity for brands willing to generate robust stability data. A cosmetic testing laboratory conducting thorough photostability and long-term stability testing isn’t just ticking a compliance box — it’s building a documentation file that positions a brand to respond quickly as the regulatory framework evolves.

How ICH Q1B Photostability Testing Actually Works

ICH Q1B is the guidance document from the International Council for Harmonisation that specifically governs photostability testing of new drug substances and products. Because US sunscreens are OTC drugs, it applies directly — and it’s more technically demanding than most brand-side formulators realize.

The guideline defines two acceptable light source options. Option 1 uses a D65/ID65 lamp, which simulates outdoor daylight and window-glass-filtered daylight respectively — a full-spectrum source delivering both visible and UV energy simultaneously. Option 2 uses a combination of a cool white fluorescent lamp (visible range) and a UV fluorescent lamp, run in tandem.

Regardless of which option your cosmetic testing laboratory uses, the minimum exposure thresholds are fixed: 1.2 million lux hours of visible light and 200 Wh/m² of UV energy. To put the UV threshold in practical terms, 200 Wh/m² is roughly equivalent to three to five days of peak summer UV exposure in Southern California — a relevant benchmark for brands targeting California markets and dealing with distribution chains that may leave products in vehicles or storage units during summer months.

The test is run on multiple sample configurations simultaneously:

• Bulk product in direct exposure — a thin layer or open container, with no packaging barrier
• Product in primary packaging — the container the consumer actually receives
• Dark controls — identical samples stored in the dark at the same temperature

That last point matters more than people expect. Dark controls run alongside every photostressed sample to isolate light-driven degradation from thermal degradation occurring at the same time. Without dark controls, you can’t cleanly attribute what you’re seeing to photodegradation specifically.

What you’re measuring post-exposure: active ingredient potency by HPLC assay, SPF retention if photo-SPF testing is incorporated, physical appearance changes (color shift, phase separation, visible precipitation), and the formation of degradation products. That last one is increasingly consequential from a regulatory standpoint. Some photodegradation products of organic UV filters are themselves potentially bioactive — which is part of why FDA’s Category III classification is tied to safety data gaps, not just efficacy gaps.

The Avobenzone Photodegradation Problem Labs Are Built to Catch

Avobenzone deserves its own section because it illustrates precisely why ICH Q1B testing is non-negotiable for any formula containing it.

In its ground state, avobenzone exists predominantly in an enol tautomeric form that absorbs UVA radiation efficiently. UV exposure drives a portion of the molecule into a keto form that can undergo irreversible photodegradation. Without a photostabilizer — compounds like octocrylene, bisoctrizole, or bemotrizinol (the latter two not yet approved for US use under the OTC monograph) — this process becomes self-amplifying. Degraded avobenzone generates reactive species that accelerate further breakdown in surrounding molecules.

The practical effect: SPF and UVA protection values measured at time-zero may bear little resemblance to what a consumer gets from a product that’s been sitting in a beach bag or a car for three months. A properly run ICH Q1B study will quantify exactly how much active content remains after the specified light exposure. Long-term stability testing at 25°C / 60% relative humidity will show you what happens across 12 months of real-world shelf time.

Three failure patterns appear most consistently in avobenzone-containing formulas when tested rigorously:

1. Active content loss exceeding 10% from label claim in nominally stabilized systems — often traced to a formulation incompatibility between the photostabilizer and an emulsifier or preservative rather than absence of a photostabilizer
2. SPF drift without corresponding UVA drift under accelerated conditions, suggesting selective degradation of the UVB-absorbing actives co-formulated alongside avobenzone
3. Yellowing or browning of the finished product under photo-stress, caused by chromophore-forming degradation products that aren’t visible at room temperature but appear under ICH Q1B exposure conditions

Any of these findings in a stability study is a formulation problem that needs to be resolved before regulatory submission or commercial launch — not after.

Long-Term and Accelerated Stability Under ICH Q1A(R2)

Photostability testing via ICH Q1B answers one question: what does light do to this product? It’s paired with long-term and accelerated thermal stability studies governed by ICH Q1A(R2), which answers a different one: what does time and temperature do to it?

For products intended for Zone I/II markets — which covers most of the continental United States — the standard conditions are:

• Long-term: 25°C ± 2°C / 60% RH ± 5% RH, with data timepoints at 3, 6, 9, and 12 months minimum
• Accelerated: 40°C ± 2°C / 75% RH ± 5% RH for six months
• Intermediate (required if significant change occurs at accelerated): 30°C ± 2°C / 65% RH ± 5% RH

“Significant change” at the accelerated condition is defined by FDA as a 5% potency loss from the initial assay value, any degradation product exceeding its specification limit, failure to meet appearance specifications, or pH moving outside defined limits. When significant change appears at 40°C/75% RH, your proposed shelf life can no longer be supported primarily by accelerated data — you need 24 months of real-time data at long-term conditions to support a 24-month label claim.

Brands frequently underestimate how much this slows them down. The minimum real-time data required to support a 24-month shelf life claim, when accelerated data is clean, is 12 months. If accelerated data shows significant change, you wait for 24 months of real-time data. There is no workaround for this under FDA’s OTC stability expectations.

What a Defensible Stability Package Actually Looks Like

The most common mistake sunscreen brands make isn’t skipping photostability testing — most formulators know they need it. The mistake is treating stability testing as a one-time event tied to initial launch rather than a living program that follows the product.

Regulatory expectation is clear: any post-approval change that could affect product quality requires stability assessment. That includes a change in active ingredient supplier, a change in manufacturing site or process, a reformulation to address a supply chain issue, or a scale-up from pilot to commercial manufacturing. Each of these events requires a new or comparative stability study. The stability file is never truly “done.”

For brands listing sunscreen products on Amazon, there’s a downstream consideration that’s become increasingly practical. Amazon’s documentation requirements for SPF products have tightened significantly, and COAs without supporting stability data — particularly for products making both UVA and UVB protection claims — are drawing scrutiny. A stability package generated by an ISO 17025 accredited cosmetic testing laboratory provides the traceable, auditable documentation that survives both marketplace compliance review and FDA inspection.

The technical requirements here are demanding, but they’re not opaque. ICH Q1A(R2) and Q1B are publicly available. FDA’s 2019 proposed OTC monograph rule is in the Federal Register. And a qualified testing laboratory can map your specific formula, active ingredient concentrations, and target markets to the exact studies you need.

Start with a photostability screen before you lock your formula. Finding out your avobenzone system needs a stabilizer adjustment during formulation development costs you a few hundred dollars and a few weeks. Finding it out after you’ve ordered commercial packaging and printed labels costs you multiples of that — plus whatever goodwill a mislabeled SPF product costs you on Amazon or with an FDA reviewer.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA OTC Drug Regulatory Strategy and Submission Support — Aurora TIC provides FDA regulatory consulting for OTC drug, device, and software submissions, including ICH-aligned documentation strategies.
• Sunscreen Active and UV Filter Raw Material Testing — Ayah Labs offers global B2B raw material characterization and supplier qualification for cosmetic and pharmaceutical actives including USP and Ph.Eur. monograph testing.